Acadia Pharmaceuticals Inc. (ACAD) upgraded to Mkt Outperform with price target $7 by JMP Securities
JMP Securities rated Mkt Outperform Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) on 05/05/2009, when the stock price was $2.54.
Since then, Acadia Pharmaceuticals Inc. has gained 1140.16% as of 12/17/2014's recent price of $31.50. If you would have followed this JMP Securities's recommendation on ACAD, you would have gained 1140.15% of your investment in 2052 days.
Acadia Pharmaceuticals Inc.
is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders. The Company is developing a portfolio consisting of its four product candidates, including pimavanserin, which is in Phase III development for the treatment of Parkinson?s disease psychosis. In addition, the Company has a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma, both in collaboration with Allergan, Inc., and ACP-106 in IND-track development. The Company?s product candidates include Pimavanserin, AGN-XX/YY, AC-262271 and ACP-106. The Company maintains two wholly owned subsidiaries: ACADIA Pharmaceuticals AB based in Malmo, Sweden and ACADIA Pharmaceuticals A/S based in Denmark.
MP Securities' equity research department provides institutional clients with comprehensive industry knowledge, unique insight and actionable information. JMP's senior research analysts are charged with developing proprietary investment themes, anticipating secular and cyclical changes and producing action-oriented reports.
JMP follows companies in six industries that exhibit above-average long-term growth characteristics — Technology, Healthcare, Consumer, Real Estate, Financial Services and Business Services — and produces specialized equity research that enables investors to understand and invest in complicated growth stocks profitably.